1. Introduction {#sec1}
===============

The avermectin/milbemycin (AM) drugs are an important class of anthelmintics used in control of gastrointestinal nematodes (GIN) of livestock. This class of anthelmintics has transformed parasite control, as they are extremely safe while harboring potent broad-spectrum antiparasitic activity. However, resistance to the AMs in many species of important gastrointestinal trichostrongylid nematodes is an increasing problem worldwide and presents a major threat to livestock health and productivity ([@bib16], [@bib32], [@bib17]).

Effective nematode control programs designed to minimize the development of anthelmintic resistance (AR) should include sensitive methods to detect and monitor AR ([@bib14], [@bib35], [@bib18], [@bib7]). The fecal egg count reduction test (FECRT) is currently the preferred method for detection of AR at the farm level, however, the FECRT is labor and cost intensive ([@bib14]). Additionally, the FECRT is rather insensitive, as typically only a single dose level is tested, and can only detect resistance once it is present at relatively high levels ([@bib27]). Alternatively, *in vitro* assays can test multiple anthelmintic compounds and concentrations, providing more detailed information about the level of resistance since it is based on a dose response. *In vitro a*ssays are considered the most efficient and cost-effective strategy to detect AR ([@bib34], [@bib14], [@bib8]).

*In vitro* assays can measure the effects of anthelmintic compounds on several nematode phenotypes, including development, growth, behavior, and motility ([@bib35]). Several *in vitro* assays were developed for detecting AR in GIN of sheep including the larval development assay (LDA) ([@bib33], [@bib15]), larval feeding assay ([@bib1]), and larval migration inhibition assay (LMIA) ([@bib38], [@bib21]).

The LDA is the most widely used *in vitro* assay for detecting resistance to the AM drugs, however, the LDA is only well-validated and accurate for detecting AM resistance in *Haemonchus contortus* (*H. contortus*) and *Trichostrongylus* c*olubriformis.* This assay measures the development of nematode eggs to third-stage larvae (L3) in the presence of increasing concentrations of various analogues of anthelmintic compounds ([@bib4], [@bib15], [@bib22]). The LDA has been evaluated against numerous susceptible and resistant isolates of *H. contortus* and *T. colubriformis* and provides a powerful tool for detection of resistance to the AMs. Additionally, using the analogues ivermectin aglycone and eprinomectin clear discrimination between susceptible and resistant isolates is possible ([@bib15], [@bib10], [@bib22]), including discrimination between ivermectin and moxidectin resistance ([@bib18]). The LDA is thought to detect the effects of AM drugs on pharyngeal activity, and it has been suggested, although not proven, that AM affected larvae suffer from starvation even in the presence of an adequate food source due to drug-induced paralysis of the pharyngeal musculature ([@bib13], [@bib15]). The LDA targets development of eggs, L1, L2, and L3, and thus this assay is able to detect the activity of anthelmintics via many different developmental processes as compared to assays that only test effects on a single stage such as L3 or eggs. Unfortunately, there is little evidence that the LDA is useful for detecting AR in GIN of cattle. To the best of our knowledge, there has been only a single publication demonstrating positive results for the LDA in detecting AR in GIN of cattle ([@bib7], [@bib8]), and this was only for a single species; *Cooperia oncophora.* Since then there have been no further publications demonstrating usefulness of the LDA for detecting AM resistance in GIN of cattle. Furthermore, the usefulness of an assay that can only detect AM resistance in one species of GIN *(C. oncophora)* of cattle is limited as most populations consist of several different species, and in many of the warmer regions of the world, other species of *Cooperia* are more prevalent. More recent efforts have focused on optimization of the LMIA ([@bib6]) or alternative systems to measure motility of L3 such as the Worminator ([@bib31]).

The LMIA measures the ability of L3 to migrate through a fine-mesh sieve in the presence of increasing concentrations of an anthelmintic compound ([@bib38]). This assay has previously been shown to differentiate AM-susceptible and AM-resistant isolates of *C. oncophora* and *H. contortus*, but not *Teladorsagia circumcincta* or *Trichostrongylus colubriformis* ([@bib21], [@bib7]). The LMIA was evaluated across five laboratories in Europe and shown to exhibit low levels of variability when standardized protocols, techniques, reagents, and well-characterized laboratory isolates were used ([@bib7]). Unfortunately, limited data has been published regarding the ability of this assay to detect resistance to AMs in recent field isolates of common GIN of livestock. [@bib2] reported the LMIA produced repeatable dose responses for field isolates of *Cooperia oncophora* and *O. ostertagi*, however, the EC~50~ for ivermectin did not differ between isolates considered as AM-susceptible and AM-resistant according to the FECRT. Further, this assay has rarely been used outside of research purposes and thus its usefulness to farmers as a diagnostic assay has not been realized. Our laboratory examined this assay for discriminating resistant and susceptible isolates of several parasites with little success; with *Dirofilaria immitis* we found no significant differences in the IC~50~ of AM-susceptible and AM-resistant isolates ([@bib11]).

Our inability to detect differences between AM-susceptible and AM-resistant isolates with the LMIA led us to question what phenotype the LMIA is actually measuring and if migration is an appropriate surrogate measurement for motility. The LMIA is essentially a 'black box assay', meaning we can measure the inputs and the outputs of the assay but have no idea of the internal workings. It is unclear what level of correlation exists between motility and migration, or if there is a minimum level of motility required for migration. In the LMIA worms either migrate or do not migrate, and are typically examined at a single time point. Additionally, the LMIA requires optimization for each individual nematode species which presents a challenge for application of the LMIA in assessing resistance in field populations comprised of multiple species.

In an attempt to overcome many of the aforementioned issues, we developed a system to directly quantify motility of microscopic larval stages of GIN. This system, called the Worminator, evaluates anthelmintic activity on larval stages of parasites using computer processing of digital video recordings to quantitatively measure motility of parasites ([@bib31]). Previously, a micromotility meter was developed by [@bib3] to quantify nematode motility by measuring changes in voltage associated with perturbation of light by nematodes, however, this system did not incorporate magnification by microscopy. Alternatively, the Worminator is comprised of an inverted microscope connected to a video camera, which sends output to a software program that quantifies displacement of pixels between video frames as a measure of motility within a recorded well. Percent inhibition in motility as compared to control wells is then calculated. The ease of use and nature of the Worminator allows readings to be made at multiple time points in the assay, rather than just a single pre-determined end point. Testing of several AM drugs with L3 of *Cooperia* spp. using the Worminator produced repeatable dose response curves ([@bib31]). Based on these accomplishments, we sought to develop an *in vitro a*ssay for detection of AM-resistance in *Cooperia* spp. using the Worminator with L3 stages. Subsequently, we also evaluated laboratory and field isolates of *Cooperia s*pp. and *H. contortus* using both the Worminator and LMIA.

In the present study, we compared the AM dose response characteristics of 8 nematode isolates; *Cooperia* spp. (n = 4) and *H. contortus* (n = 4), which included both AM-susceptible and AM-resistant isolates. Worminator assays were completed with laboratory isolates of *Cooperia* spp. (abamectin, doramectin, eprinomectin, ivermectin, and moxidectin) and *H. contortus* (eprinomectin, ivermectin, and moxidectin). LMIA were completed with ivermectin for all isolates. In addition, the *H. contortus* isolates were also tested with the LDA. These results were used to evaluate the appropriateness of motility of the L3 stage as a phenotype to detect resistance to the AM class of anthelmintics.

2. Materials and methods {#sec2}
========================

2.1. Nematode isolates {#sec2.1}
----------------------

Eight isolates of GIN were examined. Details regarding the isolation and characterization of resistance status of each isolate are described by species.

### 2.1.1. *Cooperia* spp {#sec2.1.1}

Two laboratory isolates, one AM-resistant and one AM-susceptible, and two AM-resistant field isolates were tested.

#### 2.1.1.1. Avermectin susceptible *Cooperia* spp. laboratory isolate (TGA-2013) {#sec2.1.1.1}

In June of 2013, feces were collected from a herd of cattle in Thomasville, Georgia, USA where anthelmintics were not routinely used over the past thirty years. Larvae were cultured and included 78% *Cooperia* spp., 10% *Oesophagostomum* spp., 8% *Haemonchus placei,* 3% *Trichostrongylus axei,* and 1% *C. oncophora.* A three-month-old hutch-raised dairy calf presumed to be naïve to GIN was treated with a combination of levamisole and albendazole to remove any worms that might be present. Fourteen days following treatment the calf had a FEC of less than one egg per gram (EPG) and was infected orally with 30,000 L3 from this field population. To purify *Cooperia* spp. from the other species of GIN present in the field sample, we used a strategy based on differential prepatent periods, since *Cooperia* spp. (*C. punctata*, *C. pectinata*) have the shortest pre-patent period of all species that commonly infect cattle ([@bib24]). Feces were collected from the calf per rectum from d12-15 post infection. The infection became patent at d13 post infection and daily coprocultures were established. One-hundred L3 were morphologically identified from each culture and 100% of L3 were identified as *Cooperia* spp. A second hutch-raised dairy calf was rendered worm-free with a combination treatment of albendazole and levamisole, confirmed to have a FEC of less than one EPG, and orally infected with 30,000 of these *Cooperia* spp. L3, which we designated as the TGA-2013 isolate. Following patency at d14 post infection, feces were collected periodically over time, cultured, and L3 were stored at 10 °C.

The susceptibility of TGA-2013 to ivermectin was first confirmed by treating the original recipient calf (with the mixed species infection) with injectable ivermectin at 0.2 mg/kg (Noromectin^®^, Norbrook^®^ Inc. USA, Overland Park, Kansas, USA), which yielded 100% reduction in FEC. The susceptibility of the established TGA-2013 *Cooperia* spp. isolate was then examined in a FECRT using experimentally infected beef calves. Calves (n = 3) were treated with a combination of albendazole and levamisole to clear current infections with GIN and moved to concrete pens to prevent transmission of new infections. Prior to infection with the laboratory isolate, FEC performed on the calves yielded negative results (\<1.0 EPG). Ten days post-treatment, each calf was infected orally with 100,000 L3 of the TGA-2013 isolate. FECs were monitored until EPG levels stabilized, which took about 4 weeks. On d31 post-infection each calf was treated with injectable ivermectin at 0.2 mg/kg (Ivomec^®^, Boehringer Ingelheim, St. Joseph, Missouri, USA). Since, only 3 calves were tested, to increase the number of eggs counted and reduce the variability in the FECRT, 12 separate Modified-McMaster FEC with 8 EPG detection sensitivity were performed for each calf both on the day of treatment and d14 post-treatment. Mean percentage fecal egg count reduction (%FECR) was 98.4%, confirming susceptibility of this isolate to ivermectin.

#### 2.1.1.2. Avermectin-resistant *Cooperia* spp. laboratory isolate (CGA-2014) {#sec2.1.1.2}

In September of 2014, feces were collected from a herd of cattle in Calhoun, Georgia, USA previously confirmed in 2012 as having AM-resistant *Cooperia;* a FECRT using moxidectin reduced FEC by 39.2% (36.6, 41.7). Feces were cultured, and identification of recovered L3 yielded 72% *Cooperia* spp., 14% *Haemonchus placei,* and 14% *C. oncophora.* A four-month-old hutch-raised dairy calf was treated with a combination of levamisole and albendazole, confirmed to have less than one EPG, and infected orally with 50,000 L3 from this field sample. To purify *Cooperia* spp. from the other GIN present in the field sample, we used the same strategy as described above with feces collected and cultured from d13-16. A second calf confirmed to have less than one EPG was then infected with 40,000 of these *Cooperia* spp. L3, which we designated as the CGA-2014 isolate.

The susceptibility of this isolate to ivermectin was tested using a FECRT in experimentally infected calves using the same methods as described above. Mean %FECR was 47.4%, confirming this isolate as being AM-resistant.

#### 2.1.1.3. Avermectin-Resistant Cooperia field isolate 1 (Comer, Georgia, USA) {#sec2.1.1.3}

This population of parasites was confirmed resistant to topical eprinomectin in 2013 by FECRT, yielding % FECR and 95% CI of 25.9% (5.8, 43.7). Species-specific percent FECR as determined by percentage of L3 recovered in fecal cultures were −153.6% (−222.5, −92.9) and 76.8% (70.5, 82.4) for *Cooperia* spp. and *C. oncophora,* respectively. Fecal samples were obtained from the rectum of 15 calves in October of 2015, and coprocultures yielded 82% *Cooperia* spp., 8% *Oesophagostomum* spp., 2% *Haemonchus placei,* and 5% *Cooperia oncophora,* and 3% *Ostertagia* spp.

#### 2.1.1.4. Avermectin-Resistant Cooperia field isolate 2 (Colbert, Georgia, USA) {#sec2.1.1.4}

This population of parasites was confirmed resistant to injectable ivermectin at 0.2 mg/kg (Ivomec^®^, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) in September of 2015 by FECRT, yielding % FECR and associated 95% CI of −29.2% (−59.0, −2.4). Fecal samples collected from calves (n = 11) and cultured prior to treatment included 95% *Cooperia* spp., 4% *Haemonchus placei,* and 1% *Cooperia oncophora.*

### 2.1.2. Haemonchus contortus {#sec2.1.2}

Two laboratory isolates of *H. contortus*, one AM-resistant and one AM-susceptible, and two AM-resistant field isolates were tested.

#### 2.1.2.1. Avermectin-susceptible *Haemonchus contortus* laboratory isolate (UGA-SUSC) {#sec2.1.2.1}

This isolate, obtained from Boehringer Ingelheim Vetmedica, Inc., was maintained in the laboratory for many years and had never been exposed to AM drugs. The AM EC~50~ (ivermectin aglycone) and 95% confidence interval for this isolate was 0.91 nM (0.74, 1.13) as determined by DrenchRite^®^ LDA.

#### 2.1.2.2. Avermectin-resistant *Haemonchus contortus* laboratory isolate (UGA-2004) {#sec2.1.2.2}

History of this isolate was described previously ([@bib0043]). The AM EC~50~ (ivermectin aglycone) and 95% confidence interval for this isolate was 15.00 nM (11.10, 20.25) as determined by DrenchRite^®^ LDA, yielding a resistance ratio of 16.48 as compared to the UGA-SUSC isolate. This EC~50~ is consistent with resistance to ivermectin and susceptibility to moxidectin ([@bib18]).

#### 2.1.2.3. Avermectin-resistant Haemonchus field isolate 1 (Athens, Georgia, USA) {#sec2.1.2.3}

In September of 2015, feces were collected from a flock of sheep in Athens, Georgia, USA. L3 included 81% *H. contortus a*nd 19% *Trichostrongylus colubriformis/Teladorsagia circumcincta.* EC~50~ and 95% confidence interval for *H. contortus* was 19.27 nM (13.56, 27.39) as determined by DrenchRite^®^ LDA, yielding a resistance ratio of 21.18 as compared to the UGA-SUSC isolate. This EC~50~ is consistent with resistance to ivermectin and susceptibility to moxidectin ([@bib18]).

#### 2.1.2.4. Avermectin-resistant Haemonchus field isolate 2 (Ebensburg, Pennsylvania, USA) {#sec2.1.2.4}

In August of 2015, feces were collected from a flock of sheep in Ebensberg, Pennsylvania, USA. L3 included 98% *H. contortus* and 2% *Trichostrongylus colubriformis/Teladorsagia circumcincta.* EC~50~ and 95% confidence interval for *H. contortus* was 308.6 nM (16.17, 5887) as determined by DrenchRite^®^ LDA, yielding a resistance ratio of 339.12 as compared to the UGA-SUSC isolate. This EC~50~ is consistent with resistance to both ivermectin and moxidectin ([@bib18]).

2.2. Worminator assays {#sec2.2}
----------------------

Initial stock solutions of 8.0 mM were prepared for each anthelmintic using 100% DMSO as a solvent. Initial stock solutions were then diluted in 100% DMSO to yield 4.0, 1.0, 0.50, 0.25, 0.125, 0.0625, 0.0125, and 0.0 mM working stock solutions for each drug. Working stock solutions were then diluted in deionized water yielding working concentrations of 240, 60, 30, 15, 7.5, 3.75, 0.75, and 0.0 μM in 6% DMSO.

Twenty sheathed L3 were added to each well of a 96-well, non-treated, non-sterile, polystyrene, black with clear flat bottom plate (Corning Costar^®^ \#3631, Corning Incorporated, Corning, NY, USA) in 50 μL of deionized water. Drug solution (10 μL) was then added to wells to produce a final DMSO concentration of 1% and final anthelmintic concentrations of 40, 10, 5, 2.5, 1.25, 0.625, 0.156, and 0.0 μM (negative control). All concentrations were tested in triplicate. After addition of the drug, assay plates were agitated for 5 min using a Mini Shaker (TSZ-S-04, TSZ Scientific LLC, USA), and then incubated for 24 h in the dark at 26 °C. Plates were exposed to fluorescent light for 30 min to stimulate motility of L3 prior to reading ([@bib14]). Worminator readings were taken on each well for 30 s.

Mean movement units (MMU) were measured using the consensus algorithm in WormAssay 1.4.3 for each assay well ([@bib31]). MMU represent the average motility as measured by pixel displacement in an individual assay well over a given period of time. The average MMU for three technical replicates of each drug concentration were used in the statistical analysis and generation of dose response curves. Technical replicates were defined as replicate wells within the same assay plate with larvae derived from the same coproculture and drug solutions made from the same stock solution. The average MMU of the control wells was calculated as the mean of the MMU for three negative control wells per assay plate. The percent inhibition in motility at each concentration as compared to control wells was calculated as previously described by [@bib31]. A higher percentage inhibition in motility indicated a greater effect of the anthelmintic compound. Biological replicates are represented by fecal collections and respective coprocultures setup on a different day from other biological replicates. Fresh stock solutions were prepared for each biological replicate. Results represent the mean of three biological replicates and nine technical replicates.

2.3. Larval migration inhibition assays {#sec2.3}
---------------------------------------

A 24-well migration plate was prepared as previously described ([@bib11]), with the following modifications. A 28 μm nylon mesh screen (Sefar, Inc., Heiden, Switzerland) was fixed to the base of each migration tube. With the migration tubes in place, 1.0 mL of deionized water with drug concentrations corresponding to those used in the Worminator assays were added to each well. Importantly, the same L3 that were tested in the Worminator assay were used in the LMIA to allow for direct comparison between the two assays. Immediately after completing the Worminator readings, using a dissecting microscope, all 20 L3 in each well of the Worminator incubation plate were collected and gently transferred in a volume of 100 μL into the migration tubes containing the respective drug concentrations. Once all L3 were transferred to the migration tubes, an additional 400 μL of the respective incubation solution was added to the outside of the incubation tube into each well of the migration plate, being careful not to cause turbulence inside. This yielded a final volume of 1.5 mL in each well, and the LMIA plates were then incubated at 26 °C for 24 h to allow L3 to pass through the mesh screens. After 24 h, the migration tubes were gently removed and the non-migrated larvae were washed into empty wells of the assay plate using deionized water. A drop of Lugol\'s iodine was added to each well to kill the L3 and allow for accurate enumeration of migrated vs non-migrated L3 using an inverted compound microscope. All LMIA assays were completed with ivermectin as this anthelmintic compound yielded the most repeatable dose response curves and best differentiated AM-susceptible and AM-resistant isolates in Worminator assays.

2.4. Analysis of dose response {#sec2.4}
------------------------------

Dose-response curves were generated in GraphPad Prism 7.02 using a variable slope nonlinear regression model (GraphPad Software, La Jolla, California, USA, <http://www.graphpad.com/>). Drug concentrations were log~10~ transformed prior to analysis. The "log (agonist) vs response variable slope (four parameters) logistic equation" was used to generate EC~50~ values with respective 95% confidence intervals and dose response curves. Controls were plotted as 0.10 μM assigned as the x-value. No constraints were used. Error bars on dose-response curves were displayed as standard error of the mean. The coefficient of determination (R^2^) was reported for each isolate. Resistance ratios were calculated as the EC~50~ of the resistant isolate divided by the EC~50~ of the susceptible isolate. For Worminator assays, the average percentage inhibition in motility at the highest concentration of anthelmintic compound tested (MI%) was reported. For LMIAs, the percent inhibition in migration was calculated for each well and corrected migration in control wells.

3. Results {#sec3}
==========

3.1. Worminator assays {#sec3.1}
----------------------

Dose response curves for Worminator assays testing the AM-susceptible (TGA-2013) and AM-resistant (CGA-2014) isolates of *Cooperia* spp. with abamectin, doramectin, eprinomectin, ivermectin, or moxidectin are displayed in [Fig. 1](#fig1){ref-type="fig"}. The coefficient of determination (R^2^) ranged between 0.92 and 0.98 ([Table 1](#tbl1){ref-type="table"}) for all anthelmintic compounds tested against *Cooperia* spp., indicating good fit of the data with the dose-response algorithm with all compounds tested. Ivermectin yielded the highest coefficient of determination, meaning observed outcomes were best replicated by the model when ivermectin was tested as compared to other anthelmintics. Inhibition of motility as compared to control wells at the highest concentration tested (40 μM) rarely exceeded 90%, indicating that the AM drugs do not completely inhibit motility of L3 even following incubation in very high concentrations. For both laboratory isolates of *Cooperia* spp., abamectin was the most potent compound and moxidectin was the least potent compound tested. Overall, EC~50~ were consistently between 2.0 and 6.0 μM. Resistance ratios ranged between 1.00 and 1.34 for the five AM compounds tested with AM-susceptible (TGA-2013) and AM-resistant (CGA-2014) laboratory isolates of *Cooperia s*pp. Importantly, there were no significant differences in EC~50~ between the AM-susceptible and AM-resistant isolates of *Cooperia* spp. for any AM analog tested ([Table 1](#tbl1){ref-type="table"}).Fig. 1Worminator assay dose response curves for *Cooperia* spp. Dose response for inhibition of motility of third-stage larvae of avermectin/milbemycin-susceptible (TGA-2013) and avermectin/milbemycin-resistant (CGA-2014) *Cooperia* spp. following incubation with anthelmintic compounds (A: Abamectin, B: Doramectin, C: Eprinomectin, D: Ivermectin, E: Moxidectin). Circles (blue) represent the susceptible isolate and triangles (red) represent the resistant isolate. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 1Table 1EC~50~, 95% confidence intervals (CI), inhibition of motility at highest concentration tested (MI%), and resistance ratios (RR) for avermectin/milbemycin susceptible (TGA-2013) and resistant (CGA-2014) *Cooperia* spp. and susceptible (UGA-SUSC) and resistant (UGA-2004) *Haemonchus contortus* in the Worminator assay.Table 1Susceptible *Cooperia* spp.Resistant *Cooperia* spp.Susceptible *H. contortus*Resistant *H. contortus*Anthelmintic CompoundEC~50~ (CI)R^2^MI(%)EC~50~ (CI)R^2^MI(%)RREC~50~ (CI)R^2^MI(%)EC~50~ (CI)R^2^MI(%)RRAbamectin2.70[a](#tbl1fna){ref-type="table-fn"}0.9287.292.70[a](#tbl1fna){ref-type="table-fn"}0.9687.631.00Doramectin3.21 (2.81, 3.67)0.9794.833.60 (3.20, 4.05)0.9889.911.12Eprinomectin3.36 (2.64, 4.28)0.9389.094.50 (3.19, 6.37)0.9790.731.343.56 (2.89, 4.37)0.9497.364.52 (3.54, 5.77)0.8995.291.27Ivermectin3.30 (2.62, 4.15)0.9889.613.90 (3.30, 4.62)0.9786.051.182.60 (2.28, 2.96)0.9797.204.28 (3.30, 5.54)0.9287.741.65Moxidectin5.22 (4.45, 6.13)0.9689.775.55 (4.75, 6.49)0.9582.751.064.83[a](#tbl1fna){ref-type="table-fn"}0.8896.534.78[a](#tbl1fna){ref-type="table-fn"}0.8792.130.99[^1]

Dose response curves for Worminator assays testing the AM-susceptible (UGA-SUSC) and AM-resistant (UGA-2004) laboratory isolates of *H. contortus* with eprinomectin, ivermectin, or moxidectin are displayed in [Fig. 2](#fig2){ref-type="fig"}. Repeatable dose response curves as evidenced by high R^2^ values were generated, and ivermectin yielded the most repeatable dose response curves for *H. contortus* as previously identified with *Cooperia* spp. ([Table 1](#tbl1){ref-type="table"}). Resistance ratios ranged between 0.99 and 1.65. Ivermectin yielded the highest resistance ratio (1.65) and the highest coefficient of determination in the Worminator assay and therefore was used for subsequent LMIA assays with field isolates of *Cooperia* spp. and *H. contortus.* As per results with *Cooperia* spp., motility was not completely inhibited at even the highest concentration (40 μM). Interestingly, motility of the AM-resistant *H. contortus* (UGA-2004) isolate was elevated as compared to control wells when tested with concentrations of ivermectin and moxidectin between 0.156 and 2.5 μM. This phenotype was not identified with the AM susceptible *H. contortus* isolate (UGA-SUSC). The EC~50~ for ivermectin was higher for UGA-2004 as compared to UGA-SUSC, with non-overlapping 95% CI, indicating that despite having a small resistance ratio, we were able to discriminate the two isolates using ivermectin ([Table 1](#tbl1){ref-type="table"}). However, no difference was identified in the EC~50~ of AM-susceptible and AM-resistant *H. contortus* with eprinomectin or moxidectin ([Table 1](#tbl1){ref-type="table"}).Fig. 2Worminator assay dose response curves for *Haemonchus* contortus. Dose response for inhibition of motility of third-stage larvae of avermectin/milbemycin-susceptible (UGA-SUSC) and avermectin/milbemycin-resistant *H. contortus* (UGA-2004) following incubation with anthelmintic compounds (A: Eprinomectin, B: Ivermectin, C: Moxidectin). Circles (blue) represent the susceptible isolate and triangles (red) represent the resistant isolate. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

Dose response curves for inhibition in motility (Worminator) and inhibition in migration (LMIA) of *Cooperia* and *Haemonchus* laboratory and field isolates following incubation with ivermectin are displayed in [Fig. 3](#fig3){ref-type="fig"}. For *Cooperia s*pp., the Worminator yielded repeatable dose response curves, however resistance ratios ranged between 0.61 and 1.18. The LMIA yielded resistance ratios of 1.94 and 1.12 for CGA-2014 and AM Resistant *Cooperia* Field Isolate 1, respectively ([Table 2](#tbl2){ref-type="table"}). The AM Resistant *Cooperia* Field Isolate 2 yielded poor dose-response characteristics for the LMIA, leading to a low coefficient of determination, and inability to calculate a CI for the EC~50.~ Thus, the EC~50~ and resistance ratio calculated for this isolate were not reliable ([Table 2](#tbl2){ref-type="table"}).Fig. 3Dose response curves for inhibition of motility or inhibition of migration using the Worminator or Larval Migration Inhibition Assay, respectively, for third-stage larvae of *Cooperia* spp. and *Haemonchus contortus* following incubation with ivermectin. Four isolates of *Cooperia* spp. were tested including an AM-susceptible laboratory isolate (TGA-2013), AM-resistant laboratory isolate (CGA- 2014), and two AM-resistant field isolates. Three isolates of *Haemonchus contortus* were tested including an AM-susceptible laboratory isolate (UGA-SUSC) and two resistant field isolates.Fig. 3Table 2Inhibition of motility (Worminator) versus inhibition of migration (Larval Migration Inhibition Assay) of third-stage larvae of avermectin/milbemycin susceptible and resistant laboratory and field isolates of *Cooperia* spp. and *Haemonchus contortus* following incubation with ivermectin.Table 2Inhibition of MotilityInhibition of MigrationSpeciesIsolateEC~50~ (CI)R^2^RREC~50~ (CI)R^2^RR*Cooperia* sppSusceptible3.30 (2.62, 4.15)0.983.07 (2.63, 3.59)0.97Resistant3.90 (3.30, 4.62)0.971.185.97 (4.41, 8.08)0.881.94Resistant Field 12.00 (1.02, 3.92)0.950.613.44 (3.21, 3.68)1.001.12Resistant Field 22.77 (1.30, 5.92)0.900.841.34[a](#tbl2fna){ref-type="table-fn"}0.540.44*Haemonchus contortus*Susceptible2.60 (2.28, 2.96)0.977.77 × 105[a](#tbl2fna){ref-type="table-fn"}0.44Resistant Field 13.42 (2.18, 5.36)0.851.326.17 (5.09, 7.48)0.940.00Resistant Field 22.64[a](#tbl2fna){ref-type="table-fn"}0.961.020.39[a](#tbl2fna){ref-type="table-fn"}0.260.00[^2]

For *H. contortus,* EC~50~ determined by the Worminator were not different between susceptible and resistant isolates, yielding resistance ratios of 1.32 and 1.02 for the Resistant Field Isolates 1 and 2, respectively. The LMIA yielded poor dose-response characteristics for two isolates of *H. contortus,* making accurate comparisons of these to other isolates difficult ([Fig. 3](#fig3){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}).

4. Discussion and conclusion {#sec4}
============================

The present study evaluated motility of L3 as a phenotype for detection of resistance to AM drugs using the Worminator, a system that directly quantifies motility of microscopic stages of nematodes. Motility is a commonly-used phenotype for the assessment of anthelmintic activity. Both qualitative ([@bib14]) and quantitative ([@bib3]) measurements of motility have been described in the literature. A number of systems have been developed to quantitatively measure motility and test anthelmintic activity in nematodes ([@bib3], [@bib30], [@bib26], [@bib31], [@bib28]). However, few studies have evaluated quantitative motility to detect AM resistance in GIN of livestock ([@bib7], [@bib8], [@bib9]). In this study, we tested four isolates each of *Cooperia* spp. and *H. contortus* to investigate whether motility of L3 would provide a useful phenotype for detecting resistance to AM anthelmintics. To the best of our knowledge, this is the first report of quantitative evaluation of motility for detection of AM resistance in two important species of GIN of livestock using recently-established, well-characterized laboratory and field isolates with several AM analogues.

In the present work, resistance ratios were less than 2.0 between AM-susceptible and AM-resistant laboratory isolates of *Cooperia* spp. and *H. contortus* for all anthelmintic compounds tested with the Worminator ([Table 1](#tbl1){ref-type="table"}). Using field isolates, resistance ratios were also less than 2.0 and confidence interval overlapped for EC~50~ of all AM-susceptible and AM-resistant field isolates tested with the Worminator. Confidence intervals overlapped between AM-susceptible and AM-resistant laboratory isolates of *Cooperia* spp. and *H. contortus* for all drug and isolate combinations tested, except for ivermectin with *H. contortus* which yielded a resistance ratio of 1.65 ([Table 1](#tbl1){ref-type="table"}). [@bib30] reported similar results with a resistance ratio of 1.11 and overlapping 95% confidence intervals for the AM-resistant *H. contortus* Wallangra isolate and AM-susceptible *H. contortus* Kirby isolate using an alternative motility assay, xCELLigence (Roche). Since ivermectin was the only AM analog tested that differentiated AM-susceptible and AM-resistant *H. contortus,* even with a low resistance ratio of 1.65, we chose to use this analog in subsequent assays to evaluate field isolates of *Cooperia* spp. and *H. contortus* in Worminator and all LMIA tests ([Fig. 3](#fig3){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). Further, LDA resistance ratios for the *H. contortus* isolates were 16.48, 21.18, and 339.12 for the AM-resistant laboratory isolate, field isolate 1, and field isolate 2, respectively, as compared to the AM-susceptible laboratory isolate. Thus, the LDA yielded resistance ratios at least 10 times higher than those generated from the Worminator assays. These results are consistent with [@bib29] who reported resistance ratios for the AM-resistant Wallangra isolate as compared to the AM-susceptible Kirby isolate of 20.74 and 2.82 for the LDA and LMIA, respectively.

The LMIA yielded a resistance ratio of 1.94 for AM-susceptible and AM-resistant laboratory isolates of *Cooperia* spp. Furthermore, resistance ratios for field isolates of *Cooperia* spp. and *H. contortus* were both less than 1.5. Though, these field isolates were comprised of multiple species rather than a monoculture of *Cooperia s*pp., the majority of the L3 were *Cooperia s*pp. so it is unlikely that the other species had a major impact on the results of the assay. Reports that the LMIA detected differences in susceptible and resistant *H. contortus* but not *T. circumcincta* or *T. colubriformis* suggest that the LMIA may not be appropriate for field isolates comprised of multiple species ([@bib21]). It is also possible that migration of worms in the LMIA is not only a function of motility, but also involves sensory functions of L3, which has been previously reported as a potentially important aspect of AM resistance in *H. contortus* ([@bib36]). If this is true, AM drugs may impair the ability of AM-susceptible L3 to migrate through a fine mesh sieve in the LMIA, independent of their level of motility. In contrast, if AM-resistant L3 retain sensory capabilities they may retain their ability to migrate even when their motility is impaired.

Several interesting phenotypes were identified for all isolates and AM compounds evaluated with the Worminator. First, complete inhibition of motility was not achieved even at the highest concentrations (40 μM) of anthelmintics tested suggesting that AM compounds do not completely inhibit motility of sheathed L3 *in vitro*. Due to solubility limitations of the AM drugs, it is not possible to test concentrations greater than 40 μM. It appears that the AMs paralyze the central portion of L3 and the head and tail remain slightly motile, demonstrating a slight jerking motion or a very sluggish motility. Previously, [@bib13] described this phenotype in adults of *H. contortus a*s ivermectin paralyzed the mid-body region but heads and tails maintained motility. [@bib12] reported less than 70% reduction in motility of L3 of *H. contortus* following incubation with greater than 100 μM ivermectin. [@bib9] also reported 49.7--97.8% maximum percent reduction in L3 motility of six isolates of *H. contortus* following incubation with ivermectin. The dose related levels of inhibition in motility reported in [@bib9] and [@bib12] should be interpreted with caution as concentrations of ivermectin greater than 100 μM were tested, which are above the solubility limit of this compound. Thus, the actual amount of drug the worms were in contact with cannot be accurately inferred. Additionally, [@bib9] tested 10-fold dilutions of ivermectin and eprinomectin and did not report 95% confidence intervals for calculated EC~50~ and EC~99.~ Even with these limitations, it is still clear that AM compounds do not completely inhibit motility of L3 *in vitro*.

Interestingly, the concentration of AM required to inhibit the motility of L3 by 50% is more than 100-fold greater than the peak plasma concentration achieved in cattle following subcutaneous administration of 200 μg/kg of doramectin, ivermectin, or moxidectin ([@bib23]). In contrast, the concentration of AM required to inhibit larval development from the egg in AM-susceptible *H. contortus* is at least 1000 times less than that required to inhibit L3 motility. For example, the EC~50~ for the avermectin-susceptible *H. contortus* (UGA-SUSC) in the LDA was 0.82 nM while the EC~50~ in the Worminator was 2.60 μM. [@bib15] also described this phenotype, as the EC~50~ of the McMaster isolate of *H. contortus* was 1.0 nM in the LDA and 300 nM in an L3 motility assay ([@bib14]). The concentration of ivermectin required to inhibit pharyngeal pumping and development of adult *H. contortus in vitro* are 10--100 fold lower than the concentration required to inhibit motility of L3 *in vitro* ([@bib13]). To inhibit motility of L3 of *H. contortus*, the LMIA required 500-fold the concentration of ivermectin to inhibit development in the LDA ([@bib5]). This discrepancy in the concentration of anthelmintic compound required for activity suggests that the mechanism of action, expression of drug targets, penetration of drug into the tissues of the worm, and/or drug detoxification and drug efflux mechanisms may differ among life stages of GIN. For example, L3 do not feed and thus inhibition of pharyngeal pumping will not occur; consequently, paralysis in this life stage would only result from effects on the musculature of body wall ([@bib15]). The reduced sensitivity of sheathed L3 raises questions about the suitability of L3 as a stage for detecting activity of potential anthelmintic compounds. An alternative explanation for the discrepancy in concentrations *in vivo* and *in vitro* may be that subtle motility effects of the AMs such as those associated with less than 50% inhibition in motility may be relevant to parasite expulsion and thus EC~50~ values may be less important than perceived in the above discussion ([@bib19]). Rather than quantitatively evaluating motility, [@bib14] qualitatively evaluated the motility of L3 following incubation with AM compounds and defined motile larvae as those with 'normal sinusoidal trashing motility' and non-motile larvae as those moving in a 'restricted manner'. [@bib14] obtained resistance ratios from 2.7 to 8.7 with ivermectin for known resistant isolates, further suggesting that subtle changes in L3 motility characterized as 'restrictive' motility may be more important than reduction in quantitative motility by 50% as compared to control wells.

As previously reported by [@bib14], we observed an increase in motility of L3 upon exposure to fluorescent light, which may be associated with natural response to sunlight. L3 of *H. contortus* exhibited reduced motility following incubation in the absence of light at 25 °C, but exposure to light stimulated rapid sinusoidal motility for 10--15 min before returning to a low motility state by 40--60 min post exposure. In the present study, preliminary experiments demonstrated that following incubation for 24 h in the absence of light at 26 °C, exposure to fluorescent light for 30 min achieved optimum motility of L3 in control wells.

In reference to the suitability of the L3 stage of GIN for detection of AM resistance, our results clearly indicate that motility of sheathed L3 is not an appropriate phenotype for this purpose in *Cooperia* spp. and *H. contortus.* Future research efforts should evaluate alternative life stages including the L4, which may be more appropriate for detection of AM resistance. Specifically, the L4 as a feeding parasitic stage may more accurately reflect the adult *in vivo* drug-parasite interaction and therefore express a more similar resistance profile. Until appropriate and validated molecular diagnostic markers are available for detecting resistance to AM drugs, efforts should continue to focus on the development and optimization of *in vitro* assays for detection of AR.
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[^1]: The 95% confidence interval was very wide.

[^2]: The 95% confidence interval was very wide.
